An FDA advisory committee split the difference on Thursday. They didn’t give these substances a stamp of approval for mass-market drug manufacturing. But they did open the door.
The panel voted eight to six (with one abstention) to place three specific peptides on the agency’s “bulks list.” A fourth peptide, MOTs-C, narrowly missed the majority threshold, receiving seven votes in favor with two abstentions.
This distinction matters more than you might think for how patients access these drugs. Being on the bulks list means compounding pharmacies can legally use the raw materials to create custom medications for individual patients. It keeps the supply chain moving for those who want in on the peptide boom.
The meeting itself was grueling. More than 11 hours of testimony stretched over the day. The air was thick with emotion and conflicting data. FDA scientists presented their findings on four unapproved peptides: BPC-157, KVP, TB-500, and Motase-C (MOTS-C).
They were not impressed by the safety profile.
FDA staff scientists actually recommended against allowing any of the seven peptides under consideration. Their stance was clear: there isn’t enough evidence to prove these substances are safe or effective. Yet the political and cultural momentum carried the day for three of them.
The Wolverine Stack and the Influence of Wellness Culture
Peptide therapy has moved from fringe biohacking to mainstream conversation. Why? Because people like Joe Rogan are talking about it. So are wellness influencers. Even HHS Secretary Robert F. Kennedy Jr. has called himself a “big fan” of these compounds.
It’s a cultural shift as much as a medical one.
Peptides are essentially small chains of amino acids. They are smaller versions of proteins. In theory, they can do amazing things. Promoters claim they help with skin rejuvenation, hair growth, gut health, and speeding up injury recovery.
There is just one problem. The scientific evidence to back those claims is thin.
Two of the peptides on the bulks list—BPC-157 and TB-200—are part of what is known as the “Wolverine stack.” This pairing is touted for helping the body repair itself after severe injury. It’s a narrative that appeals to the post-harm aesthetic of recovery and regeneration.
BPC-157 itself has been studied primarily in animal models. Its use for treating ulcerative colitis in humans has been suggested by proponents, but human data remains sparse. The World Anti-Doping Agency warns that BPC-157 poses health risks to athletes because it has not been extensively studied in humans. That lack of study is a huge red flag for safety regulators.
The Gray Market Reality Check
For years, these peptides existed in a regulatory gray area.
In 2023, the Biden administration banned compounding pharmacies from preparing 20 specific peptides due to safety concerns. That push drove demand underground. People still wanted them. So they turned to the internet.
Today, you can buy these substances online labeled “research use only” or “not for human consumption.” But look closely at the marketing. It implies otherwise. The packaging and ads scream human application.
China and India are the major suppliers. Some have reported that crypto-funded laboratories involved in fentanyl production have pivoted to peptide manufacturing. This introduces a terrifying variable into an already risky supply chain: who is making these, and how clean are they really?
During the panel, some healthcare providers shared disturbing stories. Patients had bought gray-market peptides only to discover the products were laced with illicit substances. Contamination is not a theoretical risk; it is a current reality for those sourcing off the books.
Proponents argued that FDA recognition would actually solve this. Their logic? If patients could get these drugs through legitimate compounding pharmacies with a prescription, they wouldn’t need to buy from shady online vendors.
“I’m not going’tell you that the evidence for BPC157 is strong. It isn’t, and I won’t overclaim it,” said Anant Vinjamori, chief medical officer of Hims & Hers. “What I’d ask is that you not read ‘thin’ as ‘non-existent.'”
Hims & Hers is already preparing to launch peptide treatments. They are betting on this regulatory shift.
Confusion vs. Safety: The Core Debate
The debate boiled down to a single question: does regulatory access improve safety, or does it lend false legitimacy to unproven treatments?
John Hertig, chair of the Collaborive for Evidence-Based Medicines, took a hard line against the panel’s recommendation. He argued that placing these peptides on the bulks list sends a confusing message. Patients might see FDA-recognized bulks and assume the drugs are safe. They aren’t.
Hertig pointed out that a gray market will persist regardless. He cited GLP-1 weight-loss drugs as proof. Even though several FDA-approved versions are on the market, a thriving black market for compounded or counterfeit versions still exists.
“There’s no evidence to suggest that allowing compounding of these unproven peptides will significantly reduce the size of the gray market,” Hertig implied. He warned that it primarily serves to legitimize products that haven’t earned that status through rigorous trials.
The panel members themselves were divided. Several had ties to peptide-related businesses or telehealth clinics. Critics might call this a conflict of interest; supporters call it industry expertise. Their vote pushed the needle forward, but barely.
What Comes Next?
This isn’t the end of the conversation. The advisory panel is set to consider three more peptides on Friday. The precedent set on Thursday could shape how the FDA handles other controversial, high-demand compounds in the future.
For now, the landscape is shifting. Three peptides can now be used by compounding pharmacies to create custom prescriptions. That changes the game for biohackers, athletes, and wellness seekers who previously had no legal path to these substances.
But the warnings from FDA scientists remain on the record. The evidence is lacking. The long-term safety is unknown. You are still ingesting substances that haven’t passed the gold standard of drug approval.
The door is cracked open. But stepping through requires navigating a minefield of regulatory ambiguity and personal risk. Are you ready for what comes next?
